Intravenous Solutions Market – By Type, By Composition, By Age Group, By Application, By End Use & Global Forecast, 2025 – 2034

Intravenous Solutions Market Size

The global intravenous solutions market size was valued at USD 13.9 billion in 2024 and is expected to reach USD 29.6 billion in 2034, growing at a CAGR of 8% from 2025 to 2034. Intravenous (IV) solutions, or IV fluids, are sterile liquids injected into a patient’s bloodstream via a vein. These solutions are employed to maintain a patient’s hydration, administer medications, and supply needed nutrients to patients that cannot ingest them or maintain electrolyte balance.
 

The malnutrition around the world is on the rise, which is leading to more demand for intravenous solutions in emerging as well as developed markets. For instance, according to the data from the World Health Organization (WHO), malnutrition was a leading cause of an estimated 148.1 million children under 5 years of age experiencing stunted growth. Moreover, several factors such as rising chronic diseases and food scarcity further accelerate the market growth. The WHO further estimates that more than 3 billion people around the globe are not able to afford a healthy meal which not only increases malnourishment but also shows the glaring need for better access to nutrition.
 

In addition, the surging demand for IV solutions in neonatal and pediatric wards is mainly attributed to a large percentage of preterm births. Preterm birth, which happens prior to 37 weeks of gestation, remains a global challenge because it is associated with morbidity and mortality.
 

According to WHO, in 2020, there were 13.4 million preterm births worldwide, whereas the preterm birth complications were the leading cause of deaths in children under five and accounted for around 900,000 lives in 2019. Further, the relative annual incidence is 4 - 16% across different countries. Thus, intravenous solutions, such as parenteral nutrition (PN), are necessary in providing essential nutrients as well as hydration to preterm infants, thereby promoting industry expansion.
 

 Intravenous Solutions Market Trends

• Healthcare providers are preferring IV solutions which are customized and pre-mixed. These solutions eliminate the need for manual compounding, thereby the risk of contamination and preparation errors is reduced. This trend is particularly evident as precision and safety are being emphasized while administering the IV solutions.
   
• The key players in the market are focusing on providing pre-mixed IV solutions to the end users in order to enhance their overall operational efficiency. For instance, Baxter's Clinimix is a premixed parenteral nutrition. With up to 80 grams of amino acids per liter, it is a ready-to-use nutritional solution.
   
• Moreover, home healthcare is observed as an advancing trend as patients are willing to have treatments in the comfort of their homes. Further, advances in infusion solutions and remote healthcare, which is expected to reach USD 33.5 billion by 2032, are supporting this shift.
   
• Furthermore, usage of multi-chamber bags (MCBs) is on the rise in home parenteral nutrition and the methods of delivery of PN vary geographically, compounded PN bags being favoured in some areas and market-authorized multi-chamber bags (MCBs) in others.
   
• Another focus area for manufacturers is sustainable packaging, which involves the use of eco-friendly adhesives and recycled materials.
   
• For instance, Baxter's Cuernavaca site in Mexico has transitioned to water-based adhesives instead of solvent-based for cardboard shipping boxes used in distributing IV solutions and renal products (6L and Twin Bag). Such initiatives are anticipated to augment the market growth.
   

Intravenous Solutions Market Analysis

Based on type, the market is segmented into total parenteral nutrition and peripheral parenteral nutrition. The global market for intravenous solutions was valued at USD 11.6 in 2021. The peripheral parenteral nutrition segment dominated the market with the largest revenue of USD 8.4 billion in 2024.
 

• Peripheral parenteral nutrition (PPN) is a method which is commonly used for patients that are dependent on short-term nutritional aid, as it supplies vital components such as amino acids, dextrose and lipids through peripheral veins.
   
• PPN can boost nutritional balance, prevent further nutrition loss, and rectify deficiencies which patients with limited oral intake or enteral nutrition struggle with by supplying micromolecules and macromolecules in appropriate measure.
   
• Studies show a positive correlation between patient satisfaction and timely PPN administration. For instance, a nutrition focused report from the Journal of Parenteral and Enteral Nutrition states that patients on PPN have a lower chance of developing infection or metabolic problems than those that were not placed on nutritional support.
   
• In addition, there have been greater incidence of cases that need temporary nutrition support, such as patients after gastrointestinal surgeries, patients with mild malabsorption syndromes or patients with acute conditions. Therefore, the market is expected to grow in the forecast period owing to the aforementioned factors.
   

Based on composition, the intravenous solutions market is segmented into carbohydrates, vitamins and minerals, single-dose amino acids, parenteral lipid emulsion, and other compositions. The carbohydrates segment emerged as a dominant segment in the market, accounting for 40.6% of revenue share in 2024 and is expected to reach by USD 12.2 billion in 2034.
 

• Carbohydrates primarily exist as dextrose, an essential part of an intravenous solution which serves as an energy reservoir for the patients that cannot receive nourishment orally or through an enteral method. IV solutions with dextrose have continually increased their market share as they are essential in providing carbohydrate energy deficits among critical care patients all over the world.
   
• Dextrose-based IV solutions provide necessary caloric support, preventing catabolism of lean body mass and ensuring adequate energy for cellular processes, particularly in malnourished or critically ill patients.
   
• Further clinical evidence supports that supplementation of carbohydrates is important for metabolic maintenance. For instance, research from ‘Critical Care Medicine’ reveals that the use of dextrose enriched IV therapy lowers the incidence of hypoglycemia and aids recovery for postoperative and trauma patients.
   
• Also, programs like Enhanced Recovery After Surgery (ERAS) also appreciate the use of intravenous carbohydrate solutions with the surgery for better recovery of patients, thereby boosting demand for IV solutions.
   

Based on age group, the intravenous solutions market is segmented into pediatric, adults, and geriatric. Geriatric segment accounted for the largest revenue share of 48.8% in 2024.
 

• Geriatric patients are quite vulnerable to dehydration as their thirst sensation is lowered, they undergo certain mobility issues, or other health conditions, which makes rapid hydration a crucial factor. IV solutions offer an efficient way to deliver essential nutrients and fluids, which can cover the deficiencies that could otherwise worsen frailty or exacerbate chronic illnesses.
   
• Moreover, patients in this age group also face difficulty swallowing food which results in poor appetite. They also deal with various gastrointestinal disorders, complicating nutrient absorption. IV solutions can eliminate these challenges by directly administering fluids, ensuring effective treatment.
   
• Further, an increasing geriatric population is expected to bolster this market in the forecast period. For instance, according to WHO, by 2030, 1 in 6 people in the world will be aged 60 years or over. Moreover, the population of people aged 60 years and over is projected to double (2.1 billion) by 2050. Thus, the growing geriatric population boosts the requirement for IV solutions, thereby accelerating market growth.
   

Based on application, the intravenous solutions market is segmented into nutritional support, blood transfusion, fluid and electrolyte balance and other applications. Nutritional support segment dominated the market accounting for USD 6.2 billion in 2024.
 

• The leading position within this segment is attributed to the increased percentage of people suffering from malnutrition, chronic diseases and patients recovering from surgery and needing parental nutrition.
   
• Treatment for malnutrition is a big issue on the global scale. WHO estimates that around 45 million children below the age of 5 are suffering from wasting which is a severe stage of malnutrition. This has boosted the need for IV nutritional support in hospitals, ICUs and pediatric units.
   
• Moreover, certain gastrointestinal disorders like Crohn’s disease, short bowel syndrome and pancreatitis make it difficult to absorb nutrients, which increases the requirement for IV-administered nutrition.
   
• Furthermore, critically ill and post-operative patients are frequently facing severe malnutrition. These patients need parental nutrition if they want to recover fully.
   
• Moreover, IV-based nutritional support further escalates with the elderly population who are already malnourished and having difficulty feeding themselves.
   

Based on end use, the intravenous solutions market is segmented into Hospitals and clinics, ambulatory surgery centers and home care settings. Hospitals and clinics segment accounted for the largest revenue share of 58.8% in 2024.
 

• Hospitals are the primary users of the IV solutions since they are integral in fluid resuscitation, parenteral drug administration, electrolyte balance, and nutrition support for patients during surgeries, trauma, severe dehydration, and chronic illnesses.
   
• Clinics are adopting IV Therapy for short-term treatments and daycare procedures for managing chronic diseases, contributing significantly to the growth of the market.
   
• The increasing occurrence of chronic diseases, such as cancer and kidney, as well as gastrointestinal disorders, is propelling the need for IV nutrition and hydration therapy in hospitals and specialized clinics.
   
• In addition, the market share for this segment is expected to be bolstered by strengthening healthcare infrastructure, rising rates of hospitalization, and further spending in updated IV formulations.
   

North America:

The U.S. intravenous solutions market is expected to grow significantly, reaching USD 10.6 billion by 2034. Moreover the U.S. revenue has increased considerably from USD 4.2 billion in 2021, to USD 4.4 billion in 2022 and USD 4.7 billion in 2023.
 

• The high preterm birth rates in the U.S. are a significant contributor in the growth of this market. For instance, according to the statistics from the Center for Disease Control and Prevention, in 2023, preterm birth rate was 10.41%, similar to the rate of 10.38% in 2022.
   
• In addition to this, the U.S. Food and Drug Administration (FDA) has implemented rigorous standards for IV solutions, driving the development of high-quality products with enhanced safety, efficacy, and stability to meet the growing demand for effective treatments in hospitals and outpatient settings.
   

Europe:

The UK intravenous solutions market is projected to experience steady growth between 2025 and 2034.
 

• In the UK, the intravenous (IV) solutions market is expected to grow considerably due to surge in procedures such as chemotherapy and other nutritional therapies.
   
• According to the House of Commons Library (the UK Parliament), in 2023, there were 138,579 cancer deaths in the UK which accounted for a 9 percent incline since 2001. Such accelerating figures of cancer patients has increased the need for IV solutions.
   

Asia Pacific:

Japan’s intravenous solutions market is poised to witness lucrative growth between 2025 – 2034.
 

• Japan has observed an increasing burden of gastrointestinal disease, which is a reason promoting market growth in the forecast period. According to NCBI, since 1990, cancer has been a major contributor for gastrointestinal related deaths in Japan. Although cancer-associated age-standardized mortality rates and DALYs are decreasing, crude rates have been increasing.
   
• Moreover, Japan has a massive aging society; according to Statista, as of November 2023, around 36.35 million people in Japan were estimated to be over 65 years of age. Therefore, it is expected that an aging society will heavily affect the disease burden in Japan in near future and hence NCBI has estimated the gastrointestinal disease burden to rise by 2035, further fostering the IV solution market.
   

Middle East and Africa:

The intravenous solutions industry in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is also experiencing a shift in population demographics. For instance, the number of people aged 60+ is expected to increase five times from 2 million (5.9% of the total population) in 2020, reaching 10.5 million by 2050.
   
• Such high trends in the aging population are expected to increase the demand for intravenous solutions in coming years.
   

 Intravenous Solutions Market Share

The market is largely dominated by the 4 top players which include Baxter International Inc., Fresenius Kabi AG, B. Braun Melsungen AG, and ICU Medical, Inc. accounting for 60% of the market share. These companies compete with one another based on various factors including, but not limited to, product line offered, sales and distribution capabilities, and sophistication of IV formulation technology. In addition, joint efforts with hospitals, research centers, and governmental health institutions are equally as important for marketing expansion, compliance to regulations, and innovation of new products in IV Therapy. These partnerships are also expected to develop new novel IV formulations, methods to increase the compatibility of drugs, and new infusion devices which will lead to further market expansion.
 

Moreover, key players are also increasing their manufacturing capacity to increase the meet the demand from end users. For instance, B. Braun announced in October 2024, that it has increased its capacity of manufacturing IV fluids in Irvine, CA and Daytona Beach, FL. The company expected to increase the production levels by 20% in coming 20 weeks. Moreover, digital health platforms and telemedicine services are also changing patient preferences, increasing the need for outpatient and home IV therapy, and enabling leading participants to enhance their share in the market.
 

 Intravenous Solutions Market Companies

Some of the eminent market participants operating in the intravenous solutions industry include:

• AdvaCare Pharma
• Amanta Healthcare
• Axa Parenterals
• B. Braun
• Baxter International
• Fresenius Kabi
• Grifols
• ICU Medical
• JW Life Science
• Otsuka Pharmaceutical
   
• Baxter International focuses on advancing innovation from product development to maintain the edge in the market. For instance, in September 2021, the company launched the premix Norepinephrine Bitartrate in 5% Dextrose Injection for treatment of severe acute hypotension after receiving approval from the FDA which strengthened Baxter’s position in the market of intravenous solutions.
   
• B. Braun is a key player in intravenous solutions having strong global presence. The company has over 63,000 employees in over 60 countries.
   
• ICU Medical implements tactics such as forming mergers or acquisition partnerships, to strengthen their market position. For instance, ICU Medical Inc. acquired Smiths Medical in January 2022 which enabled the company to add ambulatory syringe infusion pumps, vascular access equipment, and comprehensive critical care products to their offerings.
   

Intravenous Solutions Industry News:

• In June 2024, Grifols S.A. announced that Biotest received FDA approval for Yimmugo, an intravenous immunoglobulin therapeutic for treating primary immunodeficiencies. This approval extended the company’s IV solutions portfolio and strengthened its market positioning.
   
• In November 2024, ICU Medical, Inc. partnered with Otsuka Pharmaceutical Factory to enhance supply chain resilience and innovation in North American IV solutions, leveraging OPF’s Asian manufacturing expertise and ICU Medical’s regional production and distribution capabilities to strengthen market position and meet rising healthcare demands.
   
• In March 2022, Fresenius Kabi AG announced the acquisition of Ivenix, Inc. Ivenix’s advanced infusion system, combined with Fresenius Kabi’s intravenous fluids and infusion therapy offerings, was expected to create a comprehensive portfolio of infusion products for U.S. hospitals. This acquisition reinforced Fresenius Kabi’s position in the market, enhancing its ability to deliver innovative and integrated solutions to healthcare providers.
   

The intravenous solutions market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Total parenteral nutrition
• Peripheral parenteral nutrition

Market, By Composition

• Carbohydrates
• Vitamins and minerals
• Single-dose amino acids
• Parenteral lipid emulsion
• Other compositions  

Market, By Age Group

• Pediatric
• Adults
• Geriatric

Market, By Application

• Nutritional support
• Blood transfusion 
• Fluid and electrolyte balance
• Other applications

Market, By End Use

• Hospitals and clinics
• Ambulatory surgery centers
• Home care settings

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE